Aminopeptidase N (EC 3.4.11.2) inhibitors (2006 2010): A patent review

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 8, 2011, Pages 1241-1265

  Su, Li ^a   Fang, Hao ^a   Xu, Wenfang ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

aminopeptidase N; analgesia; angiogenesis; bestatin; degradation; dual inhibition; enkephalin; enzyme activity; inhibitor; invasion; neutral endopeptidase; selectivity; tumor; ZBG

Indexed keywords

ENZYME INHIBITOR; MICROSOMAL AMINOPEPTIDASE; MICROSOMAL AMINOPEPTIDASE INHIBITOR; UNCLASSIFIED DRUG;

ANALGESIA; DRUG ACTIVITY; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; INFLAMMATION; NONHUMAN; PATENT; REVIEW; VIRUS INFECTION;

ANIMALS; ANTIGENS, CD13; ENZYME INHIBITORS; HUMANS; PATENTS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79960681686     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2011.587002     Document Type: Review

References (73)

1. Antczak C, DeMeester I, Bauvois B. Ectopeptidases in pathophysiology. Bioessays 2001;23:251-26
2. Antczak C, DeMeester I, Bauvois B. Transmembrane proteases as diseasemarkers and targets for therapy. J Biol Regul Homeost Agents 2001;15:130-9 (Pubitemid 32717549)
3. Su L, Fang H, Yang K, et al. Design, synthesis and biological evaluation of novel L-lysine ureido derivatives as aminopeptidase N inhibitors. Bioorg Med Chem 2011;19:900-6
4. Menrad A, Speicher D, Wacker J, et al. Biochemical and functional characterization of aminopeptidase N expressed by human melanoma cells. Cancer Res 1993;53:1450-5 (Pubitemid 23097131)
5. Hashida, H, Takabayashi A, Kanai M, et al. Aminopeptidase N is involved in cell motility and angiogenesis: Its clinical significance in human colon cancer. Gastroenterology 2002;122:376-86 (Pubitemid 34116989)
6. Saiki I, Fujii H, Yoneda J, et al. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int J Cancer 1993;54:137-43 (Pubitemid 23137011)
7. Zhang X, Xu W. Aminopeptidase N (APN/CD13) as a target for anti-cancer agent design. Curr Med Chem 2008;15:2850-65
8. Ishii K, Usui S, Sugimura Y, et al. AminopeptidaseN regulated by zinc in human prostate participates in tumor cell invasion. Int J Cancer 2001;92:49-54 (Pubitemid 32187031)
9. Yoneda J, Saiki I, Fujii H, et al. Inhibition of tumor invasion and extracellularmatrix degradation by ubenimex (bestatin). Clin Exp Metastasis 1992;10:49-59
10. Fujii H, Nakajima M, Aoyagi T, et al. Inhibition of tumor cell invasion and matrix degradation by aminopeptidase inhibitors. Biol Pharm Bull 1996;19:6-10 (Pubitemid 26060548)
11. Fukasawa K, Fujii H, Saitoh Y, et al. Aminopeptidase N (APN/CD13) is selectively expressed in vascular endothelial cells and plays multiple roles in angiogenesis. Cancer Lett 2006;243:135-43 (Pubitemid 44508648)
12. Kwon H, Shim J, Kim J, et al. Betulinic acid inhibits growth factor-induced in vitro angiogenesis via the modulation of mitochondrial function in endothelial cells. Jpn J Cancer Res 2002;93:417-25 (Pubitemid 34506252)
13. Aozuka Y, Koizumi K, Saitoh Y, et al. Anti-tumor angiogenesis effect of aminopeptidase inhibitor bestatin against B16BL6 melanoma cells orthotopically implanted into syngeneic mice. Cancer Lett 2004;216:35-42 (Pubitemid 39410494)
14. Jardinaud F, Banisadr G, Noble F, et al. Ontogenic and adult whole body distribution of aminopeptidase N in rat investigated by in vitro autoradiography. Biochimie 2004;86:105-13 (Pubitemid 38317458)
15. Kanayama N, Kajiwara Y, Goto J, et al. Inactivation of interleukin-8 by aminopeptidase N (CD13). J Leukocyte Biology 1995;57:129-34
16. Giros B, Gros C, Solhonne B, et al. Characterization of aminopeptidases responsible for inactivating endogenous (Met5)enkephalin in brain slices using peptidase inhibitors and anti-aminopeptidase M antibodies. Mol Pharmacol 1986;29:281-7 (Pubitemid 16127007)
17. Matsuda N, Katsuragi Y, Saiga Y, et al. Effects of aminopeptidase inhibitors actinonin and amastatin on chemotactic and phagocytic responses of human neutrophils. Biochem Int 1988;16:383-90
18. Ahmad S, Ward P. Role of aminopeptidase activity in the regulation of the pressor activity of circulating angiotensins. J Pharmacol Exp Ther 1990;252:643-50 (Pubitemid 20101879)
19. Zini S, Fournie-Zaluski M, Chauvel E, et al. Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: Predominant role of angiotensin III in the control of vasopressin release. Proc Natl Acad Sci USA 1996;93:11968-73 (Pubitemid 26347232)
20. Bauvois B, Dauzonne D. Aminopeptidase-N/CD13 (EC 3.4.11.2) Inhibitors: Chemistry, Biological Evaluations, and Therapeutic Prospects. Med Res Rev 2006;26:88-130
21. Mina-Osorio P. The moonlighting enzyme CD13: old and new functions to target. Trends Mol Med 2008;14:361-71
22. Inagaki Y, Tang W, Zhang L, et al. Novel aminopeptidase N (APN/CD13) inhibitor 24F can suppress invasion of hepatocellular carcinoma cells as well as angiogenesis. BioSci Trends 2010;4:56-60
23. Chen H, Noble F, Coric P, et al. Organophosphonic inhibitors as transition state analogues of enkephalin-degrading enzymes: a class of central analgesics. Proc Natl Acad Sci USA 1998;95:12028-33
24. Ho Jeong K. N-hydroxy-2-[(2- naphthalenyl)thio]acetamide, its preparation method and novel aminopeptidase-N inhibitor containing that compound. KR06019361; 2006
25. Rich D, Moon B, Harbeson S. Inhibition of aminopeptidases by amastatin and bestatin derivatives. Effect of inhibitor structure on slow-binding processes. J Med Chem 1984;27:417-22 (Pubitemid 14133727)
26. Yang E, Shim J, Woo H, et al. Aminopeptidase N/CD13 induces angiogenesis through interaction with a pro-angiogenic protein, galectin-3. Biochem & Biophy Res Commun 2007;363:336-41 (Pubitemid 47484337)
27. Lee J, Shim J, Jung S, et al. N-Hydroxy- 2-(naphthalene-2-ylsulfanyl)- acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity. Bioorg Med Chem Lett 2005;15:181-3 (Pubitemid 39575808)
28. Shim J, Park H, Lee J, et al. Global and focused transcriptional profiling of small molecule aminopeptidase N inhibitor reveals its mechanism of angiogenesis inhibition. Biochem Biophy Res Commun 2008;371:99-103
29. Roques B. Amino acid derivatives containing a disulfanyl group in the form of mixed disulfanyl and aminopeptidase N inhibitors. WO07048787; 2007
30. Roques B. Amino acid derivatives containing a disulfanyl group in the form of mixed disulfanyl and aminopeptidase N inhibitors. US09012153; 2009
31. Roques B. Amino acid derivatives containing a disulfanyl group in the form of mixed disulfanyl and aminopeptidase N inhibitors. US09131509; 2009
32. Stanovic S, Boranic M. Membrane metalloendopeptidase (CD10/CALLA): distribution, physiologic and pathophysiologic functions and its inhibitors. Lijec Vjesn 1998;120:131-7
33. Noble F, Benturquia N, Bilkei-Gorzo A, et al. Use of preproenkephalin knockout mice and selective inhibitors of enkephalinases to investigate the role of enkephalins in various behaviours. Psychopharmacology 2008;196:327-35
34. Guindon J, Beaulieu P. The role of the endogenous cannabinoid system in peripheral analgesia. Curr Mol Pharmacol 2009;2:134-9
35. Neubert K. Novel dual peptidase inhibitors as prodrug for the therapy of inflammatory and other disorders. WO07057128; 2007
36. Wolf G, Scherberich J, Fischer P, et al. Isolation and characterization of dipeptidyl aminopeptidase IV from human kidney cortex. Clin Chim Acta 1989;179:61-71
37. Bank U, Tadje J, Helmuth M, et al. Dipeptidylpeptidase IV and alanyl-aminopeptidases as a new target complex for the treatment of autoimmune and inflammatory diseases-proof of concept in a mouse model of colitis. Adv Exp Med Biol 2006;575:143-5
38. Ansorge S, Bank U, Heimburg A. Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med 2009;47:253-61
39. Reinhold D, Biton A, Pieper S, et al. Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation. Int Immunopharmacology 2006;6:1935-42 (Pubitemid 44855698)
40. Ansorge S. use of DPIV and APN inhibitors for the treatment of dermatalogical diseases involving the hyperproliferation and modified differentiation conditions of fibroblasts. US07042938; 2007
41. Bernard P. Peptide-based compounds as new inhibitors of metallo-ectopeptidase, compositions comprising said compounds and their pharmaceutical and cosmetic uses. WO08096276; 2008
42. Xu W. Preparation of basic amino acid derivatives as metalloproteinase inhibitors. CN101481325; 2009
43. Liu Y, Shang L, Fang H. Design, synthesis, and preliminary studies of the activity of novel derivatives of N-cinnamoyl-L-aspartic acid as inhibitors of aminopeptidase N/CD13. Bioorg Med Chem 2009;17:7398-404
44. Mou J, Fang H, Liu Y, et al. Design, synthesis and primary activity assay of bi- or tri-peptide analogues with the scaffold L-arginine as amino-peptidase N/CD13 inhibitors. Bioorg Med Chem 2010;18:887-95
45. Xu W. Preparation of 2-amino-1-(4- nitrophenyl)-1-ethanol compounds as metalloproteinase inhibitors. CN101503373; 2009
46. Yang K, Wang Q, Su L. Design and synthesis of novel chloramphenicol amine derivatives as potent aminopeptidase N (APN/CD13) inhibitors. Bioorg Med Chem 2009;17:3810-17
47. Xu W. Preparation of chiral ethylenediamine derivatives as metalloproteinase inhibitors. CN101357893; 2009
48. Beaulieu P, Wernic D, Duceppe J, et al. Large scale preparation of (2S,3S)-N-Boc-3-amino-1,2-epoxy-4- phenylbutane: a key building block for HIV-protease inhibitors. Tetrahedron Lett 1995;36:3317-20
49. Shang L, Wang Q, Fang H. Novel 3-phenylpropane-1,2-diamine derivates as inhibitors of aminopeptidase N (APN). Bioorg Med Chem 2008;16:9984-90
50. Xu W. Preparation of alpha-aminoacyl cyclic imide-like peptide compounds as matrix metalloproteinase inhibitors. CN101538311; 2009
51. Li Q, Fang H, Wang X. Novel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. Design, chemistry and activity evaluation. Part I. Eur J Med Chem 2009;44:4819-25
52. Li Q, Fang H, Wang X, et al. Novel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. tructure-based design, chemistry and activity evaluation. II. Eur J Med Chem 2010;45:1618-26
53. Zhang X, Fang H, Zhu H. Novel aminopeptidase N (APN/CD13) inhibitors derived from 3-phenylalanyl-N -substituted-2,6-piperidinedione. Bioorg Med Chem 2010;18:5981-7
54. Xu W. Synthesis of ubenimex N, N-dimethylethanolamine ester dihydrochloride as aminopeptidase N inhibitor for treating neoplasm. CN101531613; 2009
55. Xu Y. Specific inhibitor of CD13/APN as abortion accelerator and CD13/APN as abortion inhibitor. CN101612398; 2009
56. Wisner A, Dufour E, Messaoudi M, et al. Human Opiorphin, a natural antinociceptive modulator of opioid-dependent pathways. Proc Natl Acad Sci USA 2006;103:17979-84 (Pubitemid 44852271)
57. Rougeot C. Opiorphin peptide derivatives as potent inhibitors of enkephalin-degrading ectopeptidases. WO09124948; 2009
58. Rougeot C. Opiorphin peptide derivatives as potent inhibitors of enkephalin-degrading ectopeptidases with therapeutic use. US090253639; 2009
59. Fournie-Zulasky M.-C. Novel amino acid derivatives, method for preparing same and therapeutic use thereof. WO09138436; 2009
60. Roques B. Aminophosphonic derivatives that can be used in the therapy of pain. WO10010106; 2010
61. Zuobi K. A. Pharmaceutical composition based on peptide from camel milk. WO10072327; 2010
62. Ripka A, Rich D. Peptidomimetic Design. Current Opin Chem Biol 1998;2:441-52
63. Hurby V. Designing peptide receptor agonists and antagonists. Nat Rev Drug Discov 2002;1:847-58
64. Wang X, Zhang L, Yang K, et al. The effect of different species Aminopeptidase N Structure on the activity screening of Aminopeptidase N Inhibitor. Biol Pharm Bull 2010;33:1658-65
65. Padia H, Howell N, Kemp B, et al. Intrarenal Aminopeptidase N Inhibition Restores Defective Angiotensin II type 2-Mediated Natriuresis in Spontaneously Hypertensive Rats. Hypertension 2010;55:474-80
66. Delmas B, Gelfi J, LHaridon R, et al. Aminopeptidase N is a major receptor for the entero-pathogenic coronavirus TGEV. Nature 1992;357:417-20
67. Ren X, Li G, Liu B. Binding characterization of determinants in porcine aminopeptidase N, the cellularreceptor for transmissible gastroenteritis virus. J Biotechnology 2010;150:202-6
68. Nam E, Lee C. Contribution of the porcine aminopeptidase N (CD13) receptor density to porcine epidemic diarrhea virus infection. Vet Microbiol 2010;144:41-50
69. Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000;60:722-7 (Pubitemid 30094573)
70. Look A, Ashmun R, Shapiro L, et al. Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J Clin Invest 1989;83:1299-130
71. Ziaber J, Baj Z, Pasnik J, et al. Expression of aminopeptidase N (APN) on peripheral blood mononuclear cells surface as a marker of these cells transendothelial migration properties in the course of multiple sclerosis. Mediators Inflamm 2000;9:45-8 (Pubitemid 30399118)
72. Shimizu T, Tani K, Hase K, et al.CD13/aminopeptidase N-induced lymphocyte involvement in inflamed joints of patients with rheumatoid arthritis. Arthritis Rheum 2002;46:2330-8
73. Lai N, Wang C, Chiang H, et al. Detection of antinuclear antibodies by a colloidal gold-modified optical fiber: comparison with ELISA. Anal Bioanal Chem 2007;388:901-7 (Pubitemid 46870689)